Search research articles
Contact Us
Filters
Showing results (61-70 of 125) with videos related to
Page
of 13
Sort By:
Leukemia & Lymphoma
|
September 30, 2014
Flow cytometric sensitivity and characteristics of plasma cells in patients with multiple myeloma or its precursor disease: influence of biopsy site and anticoagulation method
Elisabet E Manasanch, Dalia A Salem, Constance M Yuan, et al.
Clinical Cancer Research : an Official Journal of the American Association for Cancer Research
|
May 13, 2022
Capture Rate of V(D)J Sequencing for Minimal Residual Disease Detection in Multiple Myeloma
Malin Hultcrantz, Even H Rustad, Venkata Yellapantula, et al.
Clinical Lymphoma, Myeloma & Leukemia
|
February 1, 2020
Phase I Study of Selinexor, Ixazomib, and Low-dose Dexamethasone in Patients With Relapsed or Refractory Multiple Myeloma
Meghan Salcedo, Nikoletta Lendvai, Donna Mastey, et al.
Leukemia & Lymphoma
|
January 15, 2013
Modeling progression risk for smoldering multiple myeloma: results from a prospective clinical study
Benjamin M Cherry, Neha Korde, Mary Kwok, et al.
Haematologica
|
June 22, 2023
Predictors of SARS-CoV-2 Omicron breakthrough infection after receipt of AZD7442 (tixagevimab-cilgavimab) for pre-exposure prophylaxis among hematologic malignancy patients
Justin C Laracy, Judy Yan, Samantha N Steiger, et al.
Research Square
|
March 3, 2023
Bortezomib, Lenalidomide and Dexamethasone (VRd) vs Carfilzomib, Lenalidomide and Dexamethasone (KRd) as Induction Therapy in Newly Diagnosed Multiple Myeloma
Carlyn Rose Tan, Andriy Derkach, David Nemirovsky, et al.
Cytokine
|
July 22, 2014
Altered cytokine and chemokine profiles in multiple myeloma and its precursor disease
Adriana Zingone, Weixin Wang, Meghan Corrigan-Cummins, et al.
Clinical Cancer Research : an Official Journal of the American Association for Cancer Research
|
August 21, 2024
A Phase 1 First-in-Human Study of the MCL-1 Inhibitor AZD5991 in Patients with Relapsed/Refractory Hematologic Malignancies
Pinkal Desai, Sagar Lonial, Amanda Cashen, et al.
Leukemia & Lymphoma
|
January 9, 2018
Predictive biomarkers and practical considerations in the management of carfilzomib-associated cardiotoxicity
Nikoletta Lendvai, Ioanna Tsakos, Sean M Devlin, et al.
Haematologica
|
October 4, 2024
Evaluating serum free light chain ratio as a biomarker in multiple myeloma
Theresia Akhlaghi, Kylee Maclachlan, Neha Korde, et al.
Page
of 13
Search research articles
Search
Showing results (61-70 of 125) with videos related to
Sort By:
Page
of 13
Leukemia & Lymphoma
|
September 30, 2014
Flow cytometric sensitivity and characteristics of plasma cells in patients with multiple myeloma or its precursor disease: influence of biopsy site and anticoagulation method
Elisabet E Manasanch, Dalia A Salem, Constance M Yuan, et al.
Clinical Cancer Research : an Official Journal of the American Association for Cancer Research
|
May 13, 2022
Capture Rate of V(D)J Sequencing for Minimal Residual Disease Detection in Multiple Myeloma
Malin Hultcrantz, Even H Rustad, Venkata Yellapantula, et al.
Clinical Lymphoma, Myeloma & Leukemia
|
February 1, 2020
Phase I Study of Selinexor, Ixazomib, and Low-dose Dexamethasone in Patients With Relapsed or Refractory Multiple Myeloma
Meghan Salcedo, Nikoletta Lendvai, Donna Mastey, et al.
Leukemia & Lymphoma
|
January 15, 2013
Modeling progression risk for smoldering multiple myeloma: results from a prospective clinical study
Benjamin M Cherry, Neha Korde, Mary Kwok, et al.
Haematologica
|
June 22, 2023
Predictors of SARS-CoV-2 Omicron breakthrough infection after receipt of AZD7442 (tixagevimab-cilgavimab) for pre-exposure prophylaxis among hematologic malignancy patients
Justin C Laracy, Judy Yan, Samantha N Steiger, et al.
Research Square
|
March 3, 2023
Bortezomib, Lenalidomide and Dexamethasone (VRd) vs Carfilzomib, Lenalidomide and Dexamethasone (KRd) as Induction Therapy in Newly Diagnosed Multiple Myeloma
Carlyn Rose Tan, Andriy Derkach, David Nemirovsky, et al.
Cytokine
|
July 22, 2014
Altered cytokine and chemokine profiles in multiple myeloma and its precursor disease
Adriana Zingone, Weixin Wang, Meghan Corrigan-Cummins, et al.
Clinical Cancer Research : an Official Journal of the American Association for Cancer Research
|
August 21, 2024
A Phase 1 First-in-Human Study of the MCL-1 Inhibitor AZD5991 in Patients with Relapsed/Refractory Hematologic Malignancies
Pinkal Desai, Sagar Lonial, Amanda Cashen, et al.
Leukemia & Lymphoma
|
January 9, 2018
Predictive biomarkers and practical considerations in the management of carfilzomib-associated cardiotoxicity
Nikoletta Lendvai, Ioanna Tsakos, Sean M Devlin, et al.
Haematologica
|
October 4, 2024
Evaluating serum free light chain ratio as a biomarker in multiple myeloma
Theresia Akhlaghi, Kylee Maclachlan, Neha Korde, et al.
Page
of 13